Ovarian Cancer

>

Latest News

Findings from the phase 2 RAMP 201 trial highlight responses with avutometinib/defactinib in those with KRAS-mutated low-grade serous ovarian cancer and other patient subgroups.
Avutometinib Combo Yields Responses in Serous Ovarian Cancer Subgroups

March 26th 2024

Findings from the phase 2 RAMP 201 trial highlight responses with avutometinib/defactinib in those with KRAS-mutated low-grade serous ovarian cancer and other patient subgroups.

Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.
Rezatapopt Yields Early Responses, Safety in Advanced Ovarian Cancer

March 24th 2024

Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.
FDA Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

March 22nd 2024

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.
CRX100 Yields Responses, Tolerability in Platinum-Resistant Ovarian Cancer

March 19th 2024

Mirvetuximab Yields HRQOL Improvement in FRα-Positive Ovarian Cancer
Mirvetuximab Yields HRQOL Improvement in FRα-Positive Ovarian Cancer

March 16th 2024

Video Series
Video Interviews
Podcasts
Latest CME Events & Activities

What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations

View More

Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS

View More

Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond

View More

Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?

View More

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

View More

Clinical Vignettes™: Integrating Novel CAR T-Cell Therapies Across Lymphoid Malignancies with an Eye Toward the Future of Care

View More

The Latest on Acute Lymphocytic Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

A Focus on Acute Myeloid Leukemia

View More

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?

View More

Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma

View More

Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer

View More

Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse

View More

Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs

View More

Community Practice Connections™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Go To PER in Chicago

May 31, 2024 - June 2, 2024

Register Now!

The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward

View More

Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment

View More

Expert Illustrations & Commentaries™: Exploring the Mechanistic Rationale for Targeting FGFR2 and Pan-FGFR in CCA

View More

Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician

View More

Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC

View More

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure

View More

The 14th Asia-Pacific Primary Liver Cancer Expert Meeting

July 18 - 20, 2024

Register Now!

23rd Annual International Congress on the Future of Breast Cancer® East

July 19-20, 2024

Register Now!

More News